EXU. Expedition Mining Inc

Imagin Medical Announces Social Media Campaign Launch

Imagin Medical Announces Social Media Campaign Launch

VANCOUVER, British Columbia and BOSTON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) is pleased to announce the launch of new social media campaigns via Twitter, Facebook and LinkedIn.

The primary goal of these new campaigns is to provide patients suffering from bladder cancer, their loved ones and the general public with an online resource to better understand the disease state as well as to provide access to up-to-date information on this disease. 

Imagin Medical intends to help patients gain control of their journey through education and innovation in the field of bladder cancer.

In addition to educational resources, Imagin Medical will be leveraging these digital channels to keep investors up to date on its corporate progress and company activities.  Members of our executive team and scientific advisory board will also regularly contribute thought leadership content.

The Company is run by an experienced Boston-based medical device executive team that has significant surgical endoscopy experience gained over decades of helping define how minimally invasive surgery is performed today.

Jim Hutchens, President & CEO, commented, “Imagin is actively building a digital market awareness ecosystem that will help not only patients, but also keep our investors informed.”

We encourage readers to follow us on Facebook (), Twitter (@) and LinkedIn () or visit our website at for further information.

About Imagin Medical

Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries (MIS). The Company’s first product, the i/Blue Imaging™ System, is based on advanced optics and light sensors and employs patented ultrasensitive imaging technology. The Company’s initial focus is bladder cancer. Learn more at

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

Contacts:

Jim Hutchens

President & CEO

Telephone: 833-246-2446

Email:

EN
17/10/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Expedition Mining Inc

Imagin Medical Inc: 1 director

A director at Imagin Medical Inc bought 150,000 shares at 0.326USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

 PRESS RELEASE

Imagin Medical to Present at the First Annual BioTuesdays Pre-JPM Virt...

Imagin Medical to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference VANCOUVER, British Columbia and BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that management will present an update on the Company’s business at the first annual on Tuesday, December 10, 2019 at 12:00 p.m. Eastern Time. The presentation will be broadcast live and archived on the Company's website at under "Events & Presentations.” About Imagin Medical Imagin Medical is a surgical ima...

 PRESS RELEASE

Imagin Medical Confirms Functional Units on Schedule for Product Desig...

Imagin Medical Confirms Functional Units on Schedule for Product Design Verification VANCOUVER, British Columbia and BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported further progress toward verification of its i/Blue Imaging System functional product. The i/Blue System is currently in the design verification stage of the development process. Since Imagin’s last progress update on July 15, 2019, the Company has purchased and received components for the initial build of the f...

 PRESS RELEASE

Imagin Medical Announces Social Media Campaign Launch

Imagin Medical Announces Social Media Campaign Launch VANCOUVER, British Columbia and BOSTON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) is pleased to announce the launch of new social media campaigns via Twitter, Facebook and LinkedIn. The primary goal of these new campaigns is to provide patients suffering from bladder cancer, their loved ones and the general public with an online resource to better understand the disease state as well as to provide access to up-to-date information on this ...

 PRESS RELEASE

Imagin Medical Announces Meeting Regarding i/Blue’s Regulatory Pathw...

Imagin Medical Announces Meeting Regarding i/Blue’s Regulatory Pathway VANCOUVER, British Columbia and BOSTON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced it recently met with the U.S. Food and Drug Administration (“FDA” or the “Agency”) to discuss its premarket approval regulatory pathway for marketing authorization. Based on the Company’s continued collaborative discussions with the Agency, Imagin anticipates pursing approval for the i/BlueTM Imaging System through a regulat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch